Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01471405
Other study ID # 8-79-52030-742
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2012
Est. completion date August 2013

Study information

Verified date January 2019
Source Ipsen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207 study.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date August 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Completed the 2-79-52030-207 study and received 12 injections of lanreotide Autogel 120 mg, regardless of efficacy at the end of this period.

- Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Czechia III. Interní klinika Karlova Univerzita Praha 2
France CHU de Rouen Bois Guillaume
France Groupement hôspitalier est Federation d'endocrinologie. Bron
France CHU Michallon Grenoble
France Hôpital Claude Huriez Lille
France CHU Timone Marseille
France Hôpital Bicêtre Paris
France Hôpital Haut Leveque Pessac
France CHU de Reims Reims
France Hôpital Larrey Toulouse
Germany Universität Duisburg-Essen Essen
Germany Klinikum der Johann Wolfgang, Goethe-Universität Frankfurt
Italy Università Federico II di Napoli Napoli
Italy Università Cattolica del Sacro Cuore Roma
Turkey Istanbul Universitesi, Cerrahpasa Tip Fakültesi Istanbul
United Kingdom Aberdeen Royal Infirmary Aberdeen
United Kingdom Christie Hospital Manchester
United Kingdom Derriford Hospital Plymouth

Sponsors (1)

Lead Sponsor Collaborator
Ipsen

Countries where clinical trial is conducted

Czechia,  France,  Germany,  Italy,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients maintained on medical treatment with lanreotide Autogel 1 year
Primary Proportion of patients receiving other medical treatments 1 year
Secondary Proportion of patients with at least one pituitary surgery 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06344650 - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting NCT02092129 - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. N/A
Completed NCT02012127 - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting NCT01265121 - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. N/A
Terminated NCT00765323 - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Phase 3
Completed NCT00500227 - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed NCT00531908 - Physiopathology of Sodium Retention in Acromegaly N/A
Completed NCT01278342 - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Phase 4
Active, not recruiting NCT01809808 - A Prospective Study of Outcome After Therapy for Acromegaly
Completed NCT00145405 - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Phase 4
Completed NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Phase 3
Recruiting NCT05401084 - Diet in the Management of Acromegaly N/A
Recruiting NCT00005100 - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly N/A
Completed NCT00521300 - Preoperative Octreotide Treatment of Acromegaly Phase 4
Completed NCT03548415 - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Phase 2
Not yet recruiting NCT04066569 - Reproducibility and Utility of OGTT in Acromegaly N/A
Not yet recruiting NCT05298891 - Hypoproteic Diet in Acromegaly N/A
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Active, not recruiting NCT03252353 - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Phase 3

External Links